Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

NCT05533697 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT05533697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05533697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Lead sponsor
ModernaTX, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 1, 2022
Completion date
February 18, 2032
Enrollment
361 (estimated)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors